Silverback Therapeutics is a clinical-stage biopharmaceutical company, established in 2016, centered around its proprietary ImmunoTAC technology platform. The company focuses on developing systemic, tissue-targeted therapeutics designed for treating cancer, chronic viral infections, and other serious diseases. This platform uniquely pairs linker-payloads that influence key disease-modifying pathways with monoclonal antibodies, targeting specific disease sites. Initially, Silverback aims to innovate in the field of immuno-oncology by developing targeted agents that enhance cancer cell destruction within solid tumors.
Positioned within the Biopharma sector, Silverback Therapeutics operates at the intersection of Biotechnology, Health Care, and Health and Wellness. The company secured an $85.00M Series C investment on September 23, 2020, with backing from renowned investors, including Pontifax, RA Capital Management, and Frazier Healthcare Partners, among others. This substantial funding underscores strong investor confidence in Silverback's innovative platform and potential market disruption.
